2025 annual financial data
Inhibikase Therapeutics 2025 Operating margin
Direct answer
Operating margin was Not calculable.
Operating income was -51,974,283 USD and net income was -48,259,189 USD.
Operating cash flow was -27,786,464 USD.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -51,974,283 USD
- Net income
- -48,259,189 USD
- Operating cash flow
- -27,786,464 USD